CRSP vs NTLA
CRSP: CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs. NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
Side-by-side fundamentals
| Metric | CRSP | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $47.24 | $11.13 | |
| Market cap as of 2026-07-23 | $4.6B | $1.6B | |
| PEG as of 2026-07-23 | -0.21 | n/a | |
| Net margin as of 2026-07-23 | -13856.5% | -597.0% | NTLA higher |
| Operating margin as of 2026-07-23 | -15754.2% | -636.6% | NTLA higher |
| ROE as of 2026-07-23 | -30.9% | -57.3% | CRSP higher |
| ROA as of 2026-07-23 | -24.5% | -46.1% | CRSP higher |
| Debt / equity as of 2026-07-23 | 0.32 | 0.00 | NTLA lower |
| Revenue growth (YoY) as of 2026-07-23 | -89.1% | +45.0% | NTLA higher |
| Revenue CAGR (3y) SEC XBRL | +43.1% | +9.1% | CRSP higher |
| Beta as of 2026-07-23 | 1.77 | 1.78 | |
| 1-year return as of 2026-07-22 close | -26.3% | -17.5% | NTLA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.